Preliminary analysis of short-term real-world outcomes of telitacicept in high-risk IgA nephropathy.

ABSTRACT:

Introduction

IgA nephropathy (IgAN) represents an important cause of end-stage kidney disease worldwide. Telitacicept has demonstrated potential in attenuating disease progression in IgAN patients. However, whether its efficacy differs between initial and alternative therapy in IgAN patients at high risk of kidney function progress (high-risk IgAN) remains unclear. This preliminary real-world study seeks to provide initial insights into this question.

Methods

We enrolled patients with primary IgAN who exhibited persistent proteinuria (≥ 0.75 g/day) and an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2 despite ≥ 3 months of supportive therapy. Participants receiving telitacicept as either initial or alternative treatment were propensity score-matched (1:1) ba

SUBMITTER: Ma Y 

PROVIDER: S-EPMC12714628 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature